Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmuCell filings document material events and governance matters for an animal health biologics company built around First Defense. Form 8-K reports record preliminary and annual financial results, board retirements and appointments, senior-officer employment agreements, and settlement of claims tied to a prior development services and commercial supply agreement.
Definitive proxy materials cover director matters, board oversight, executive compensation, and equity-award disclosures. The filing record also includes exhibits with company press releases addressing product sales, financial condition, strategic focus, and related operating updates.
ImmuCell Corporation reported preliminary, unaudited sales showing strong growth in 2026. Total product sales for the three months ended June 30, 2026 were $7.2 million, up 11.5% from $6.4 million a year earlier, driven by a 27.7% increase in domestic sales to $6.2 million. International sales for the quarter declined to $1.0 million from $1.6 million, a 38.9% decrease. For the first six months of 2026, total product sales reached $17.5 million, a 20.9% increase compared to $14.5 million in 2025, with domestic sales of $16.0 million and international sales of $1.6 million. Product-wise, Q2 2026 Tri-Shield First Defense sales were $4.9 million, up 8.3%, while Dual-Force and other sales were $2.3 million, up 19.1%. Management plans to discuss full financial results on a conference call on August 14, 2026.
ImmuCell Corp director and CEO Paul Francis Olivier te Boekhorst reported buying additional company stock. On June 18, 2026, he made an open-market purchase of 8,000 shares of ImmuCell common stock at $9.495 per share, bringing his direct holdings to 17,785 shares.
ImmuCell Corporation held its 2026 annual stockholder meeting by webcast and conference call, with 7,397,695 common shares present, representing more than 81% of eligible votes. Stockholders elected seven directors to one-year terms, each receiving over 5.16 million votes in favor with relatively few votes withheld.
Investors approved a non-binding advisory resolution on executive compensation, with 4,793,553 votes for and 92.4% of votes cast in favor. Another stockholder matter was also approved with 4,689,407 votes for and 90.39% support among votes cast. Stockholders approved an amendment to the Certificate of Incorporation regarding officer exculpation, receiving 4,851,019 votes for, which represented 53.62% of total shares outstanding.
They also ratified the Audit Committee’s selection of Wipfli LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 7,344,196 votes for, 14,645 against and 38,854 abstentions, reflecting 99.28% support among votes cast.
ImmuCell Corporation outlined a manufacturing capacity expansion focused on its flagship First Defense® product line. The Board authorized a program that shifts resources away from the previously planned in-house Re-Tain® production toward expanded First Defense® output.
The first phase will start immediately, renovating the former Re-Tain® facility and installing a new, higher-capacity freeze dryer. This phase is expected to take about 12 months and cost approximately $3.5 million. A second phase will repurpose additional Re-Tain® equipment and add automation to further expand First Defense® colostrum processing, with the goal of reliably meeting expected customer demand.
ImmuCell Corporation reported strong first-quarter 2026 results, highlighted by double-digit growth and improved profitability. Product sales rose 28.4% to $10.4 million, lifting gross margin to 45.0%. Net income increased to $1.9 million, or $0.21 per share, compared with $1.4 million, or $0.16 per share, a year earlier.
The company generated $3.4 million of free cash flow, raising cash to $6.8 million as of March 31, 2026, while maintaining solid inventory. ImmuCell also received a net $2 million payment from settling disputes with a former contract manufacturer and increased manufacturing output from about 380,000 to more than 450,000 units per month.
ImmuCell Corporation reported strong first-quarter 2026 growth, with higher sales and profitability. Product sales reached $10.36 million, up 28.4% from $8.07 million a year earlier, driven mainly by higher volumes and price increases in its First Defense® line. Net income rose to $1.94 million from $1.45 million, and basic and diluted earnings per share increased to $0.21 from $0.16. Gross profit improved to $4.66 million as cost of goods sold grew more slowly than revenue, helped by price actions and manufacturing efficiencies. Operating cash flow more than doubled to $3.57 million, boosting cash and cash equivalents to $6.81 million while total debt edged down to $8.70 million. The company also changed useful-life estimates on certain idle Re-Tain® assets, reducing quarterly depreciation by about $0.1 million. After quarter-end, ImmuCell entered a Settlement Deed under which Norbrook Laboratories agreed to pay $2.0 million, resolving a prior development and supply agreement.
ImmuCell Corporation filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to update the exhibit list only. The amendment adds a previously filed Loan Agreement with Maine Community Bank as Exhibit 10.43, corrects and clarifies descriptions and “incorporated by reference” notations for several executive compensation and plan documents, and refiles the 2025 Stock Option and Incentive Plan to match the version in the April 24, 2026 proxy statement. Updated CEO and CFO certifications are also included. The company states that its audited financial statements and other disclosures from the original filing are unchanged.
ImmuCell Corporation entered into a new settlement agreement with Norbrook Laboratories on May 8, 2026. The companies signed a Settlement Deed that resolves and releases all claims related to their 2019 Development Services and Commercial Supply Agreement, which expired March 31, 2026. Under this Settlement Deed, Norbrook will pay ImmuCell $2,000,000, providing a one-time cash benefit to ImmuCell. The agreement is governed by Northern Ireland law, contains confidentiality undertakings, and explicitly states it is not an admission of liability or wrongdoing by either party.
ImmuCell Corporation is asking stockholders to vote at its June 11, 2026 virtual annual meeting. Holders of 9,046,799 common shares as of April 13, 2026 can elect seven directors, cast an advisory “say-on-pay” vote, and ratify Wipfli LLP as auditor.
Stockholders are also asked to approve the 2025 Stock Option and Incentive Plan, which authorizes up to 650,000 shares and has 403,777 options already granted, largely contingent on approval, and to amend the charter to add Delaware-permitted officer exculpation.
The proxy highlights a leadership transition to new CEO P. Olivier te Boekhorst, a strategic focus on the First Defense® product line, efforts to partner Re-Tain®, creation of a Strategy & Technology Committee, and updated compensation and equity policies for executives and directors.
ImmuCell Corp. director Anthony DiMarco filed an initial ownership report showing a holding of non-qualified stock options. These options cover 17,899 shares of common stock at an exercise price of $7.60 per share and expire on April 15, 2036.
The options vest over three years: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares on April 15, 2029. This filing records DiMarco’s derivative equity position; it does not show any recent buy or sell transaction.